Neoplasms

All Conditions

Symptoms and General Pathology

Skin and Connective Tissue Diseases

Leiomyoma

Hemorrhage

Myofibroma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

All Drugs and Chemicals

Antineoplastic Agents

Hormones

Goserelin

Hormone Antagonists

Antineoplastic Agents, Hormonal

Women were randomised to receive no gonadotropin-releasing hormone agonist prior to myomectomy.

Women were randomised to receive 2 doses of 3.6mg of gonadotropin releasing hormone agonist prior to the myomectomy.

Women were randomised to receive 3 doses of the gonadotropin-releasing agonist (3.6mg monthly injections).

3.6mg administered monthly for 2 months prior to myomectomy

2 Doses Goserelin

3.6mg administered monthly for 3 months prior to myomectomy

3 Doses Goserelin

Dr Bharat Bassaw, MBBS FRCOG

Fibroids are common in the West Indian population (30-40% of reproductive women).Fibroids are benign growth in the womb or uterus and in order to preserve the fertility of women they, require an operation called myomectomy or shelling out of the fibroid. This procedure can be associated with large blood loss.

In current practice some obstetricians use a gonadotropin releasing hormone agonist prior to the operation to reduce blood loss. Gonadotropin releasing hormone agonist is used in current gynaecological practice to treat women with heavy periods.

In this study the investigators randomised women to either 2 or 3 doses of the gonadotropin agonist prior to their operation and no treatment. The intraoperative blood loss was measured. The study hypothesis: To determine whether administration of gonadotropin releasing hormone agonist prior to myomectomy reduces intraoperative blood loss.

Variables noted preoperatively:

* Age
* Parity
* Ethnicity
* Ultrasound findings

Variables noted intra-operatively:

* Size of largest fibroid
* Estimated blood loss

Gonadotropin-releasing Hormone Agonist Prior to Myomectomy

Phase 3 Study of Experience With a Gonadotropin-releasing Hormone Agonist Prior to Myomectomy - Comparison of 2 Versus 3 Monthly Doses.

Gonadotropin releasing hormone agonist Goserelin 3.6mg was administered for either 2 or 3 months prior to the operation.

The hemoglobin level of each woman was measured on day 1 post operative and a blood transfusion was recommended if the hemoglobin level was \<9g/dl.

The surgeons were asked to record the level of difficulty in enucleation (shelling out) of the fibroids and in securing hemostasis. They were asked to state if it was Easy, moderate or difficult.

The length of operation was calculated from the skin incision to closure (minutes).

The length of hospital stay was calculated in number of days from the date of the to the date of discharge.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Gonadotropin-releasing Hormone Agonist Prior to Myomectomy	NCT01581944	Fibroids	2 Doses Goserel... 3 Doses Goserel...	20 Years - 45 Years	Mt. Hope Maternity Hospital
Gonadotropin-releasing Hormone Agonist Prior to Myomectomy	NCT01581944	Fibroids	2 Doses Goserel... 3 Doses Goserel...	20 Years - 45 Years	Mt. Hope Maternity Hospital

Spots Global Cancer Trial Database for 3 doses goserelin